Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Schleifman, Erica B ^a   Tam, Rachel ^a   Patel, Rajesh ^a   Tsan, Alison ^b   Sumiyoshi, Teiko ^a   Fu, Ling ^a   Desai, Rupal ^a   Schoenbrunner, Nancy ^b   Myers, Thomas W ^c   Bauer, Keith ^c   Smith, Edward ^c   Raja, Rajiv ^a  

^a GENENTECH INC   (United States)

^b Chemistry and Innovation Technology   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CD135 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GENOMIC DNA; SCATTER FACTOR RECEPTOR; AKT1 PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; HRAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MET PROTEIN, HUMAN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN P21; RAS PROTEIN; STEM CELL FACTOR RECEPTOR;

AKT1 GENE; ARTICLE; AUTOMATION; BRAF GENE; CANCER GENETICS; CONTROLLED STUDY; CROSS REACTION; DATA ANALYSIS; DNA DETERMINATION; DRUG RESEARCH; EGFR GENE; FGFR3 GENE; FLT3 GENE; GENE; GENE AMPLIFICATION; GENETIC ANALYZER; GENETIC DATABASE; GENETIC PROCEDURES; HRAS GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; KIT GENE; MET GENE; MICROCHIP ANALYSIS; MICROFLUIDICS; MUTATIONAL ANALYSIS; NEXT GENERATION MUTATION MULTIANALYTE PANEL; ONCOGENE K RAS; ONCOGENE N RAS; PERSONALIZED MEDICINE; PIK3CA GENE; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; VALIDATION PROCESS; GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; PROCEDURES; VALIDATION STUDY;

DNA MUTATIONAL ANALYSIS; FMS-LIKE TYROSINE KINASE 3; GTP PHOSPHOHYDROLASES; MEMBRANE PROTEINS; MICROFLUIDICS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REPRODUCIBILITY OF RESULTS;

EID: 84899118296     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090761     Document Type: Article

References (30)

1. Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, et al. (2007) STrengthening the Reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement. PLoS Med 8: e1001117.
2. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, et al. (2010) PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23: 190-200.
3. Mittempergher L, de Ronde JJ, Nieuwland M, Kerkhoven RM, Simon I, et al. (2011) Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 6: e17163.
4. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5: e13821.
5. Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, et al. (2011) Further activation of FLT3 mutants by FLT3 ligand. Oncogene 30: 4004-4014.
6. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, et al. (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14: 6821-6828.
7. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580. (Pubitemid 28067289)
8. Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, et al. (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58: 1719-1722. (Pubitemid 28215099)
9. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, et al. (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19: 1547-1555. (Pubitemid 30175676)
10. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, et al. (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281. (Pubitemid 37255174)
11. Patel R, Tsan A, Tam R, Desai R, Schoenbrunner N, et al. (2012) Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. PLoS One 7: e51153.
12. Reichert F BK, Myers TW, Schoenbrunner NJ, San Filippo J (2012) "DNA polymerases with increased 39-mismatch discrimination". US Patent 2011/0312041A1.
13. Will SG, Tsan A, Newton N (2011) "Allele-Specific Amplification," US Patent 2010/0099110A1.
14. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, et al. (2013) Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn 15: 234-247.
15. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: Unit 10 11.
16. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, et al. (2010) Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16: 3670-3683.
17. Saal LH, Holm K, Maurer M, Memeo L, Su T, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559. (Pubitemid 40490050)
18. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
19. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444. (Pubitemid 47123510)
20. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, et al. (2010) A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 10: 101.
21. Kim MS, Jeong EG, Yoo NJ, Lee SH (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-1535. (Pubitemid 351652321)
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
23. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, et al. (2010) Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 36 Suppl 3: S56-61.
24. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, et al. (2010) Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15: 390-404.
25. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
26. Irahara N, Baba Y, Nosho K, Shima K, Yan L, et al. (2010) NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19: 157-163.
27. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, et al. (2011) PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6: e22769.
28. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50: 307-312.
29. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
30. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862.